Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pure Bioscience (PURE)

Pure Bioscience (PURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,337
  • Shares Outstanding, K 111,886
  • Annual Sales, $ 2,200 K
  • Annual Income, $ -2,400 K
  • EBIT $ -2 M
  • EBITDA $ -2 M
  • 60-Month Beta 0.59
  • Price/Sales 2.13
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.03
  • Most Recent Earnings $0.00 on 12/15/25
  • Next Earnings Date 03/16/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Products

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0388 +22.94%
on 01/02/26
0.0547 -12.80%
on 12/18/25
-0.0069 (-12.64%)
since 12/16/25
3-Month
0.0388 +22.94%
on 01/02/26
0.0830 -42.53%
on 10/30/25
-0.0243 (-33.75%)
since 10/16/25
52-Week
0.0388 +22.94%
on 01/02/26
0.2136 -77.67%
on 05/21/25
-0.0184 (-27.84%)
since 01/16/25

Most Recent Stories

More News
PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported...

PURE : 0.0477 (+13.57%)
PURE Bioscience, Inc. Announces Leadership Promotions

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE” or the “Company”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today announced that...

PURE : 0.0477 (+13.57%)
PURE Bioscience Reports Fiscal 2025 Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported...

PURE : 0.0477 (+13.57%)
PURE Bioscience Reports Fiscal 2023 Second Quarter And Six-Month Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal second quarter and six-month period...

PURE : 0.0477 (+13.57%)
PURE Bioscience Reports Fiscal First Quarter 2023 Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for...

PURE : 0.0477 (+13.57%)
PURE Bioscience Reports Fiscal 2022 Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for...

PURE : 0.0477 (+13.57%)
PURE Bioscience Reports Fiscal 2022 Third Quarter and Nine-Month Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period...

PURE : 0.0477 (+13.57%)
PURE Bioscience Reports Fiscal 2022 Second Quarter And Six-Month Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal second quarter and six-month period...

PURE : 0.0477 (+13.57%)

Business Summary

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its...

See More

Key Turning Points

3rd Resistance Point 0.0596
2nd Resistance Point 0.0538
1st Resistance Point 0.0507
Last Price 0.0477
1st Support Level 0.0418
2nd Support Level 0.0360
3rd Support Level 0.0329

See More

52-Week High 0.2136
Fibonacci 61.8% 0.1468
Fibonacci 50% 0.1262
Fibonacci 38.2% 0.1056
Last Price 0.0477
52-Week Low 0.0388

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar